Adragos Pharma GmbHa, a contract development and manufacturing organization (CDMO), signed a definitive agreement with global pharmaceutical services company Clinigen Ltd., to acquire Lamda Laboratories S.A. in Athens.

In a statement the company said that the acquisition of Lamda Laboratories significantly expands Adragos’ pharmaceutical product development, regulatory affairs and supply chain management services for its global pharmaceutical customers.

The Athens site is fully equipped with state-of-the-art equipment including the handling of potent drugs, established Quality systems and a proven track record of delivering complex developments on time for customers.

According to the company, a highly experienced management team and well-trained staff will continue to focus on complex product development for growing markets in Europe, Japan, and North America. Lamda will offer an expanded range of pharmaceutical development, regulatory affairs and supply chain management services for a wide range of dosage forms including complex and high potent oral solids, differentiated oral liquids, injectables and topical medicines.

As part of the transaction, Adragos secures royalty streams for products stemming from previous co-developments.
David Bryant, interim CEO of Clinigen Limited said: “We are pleased to have found in Adragos Pharma a trusted partner to build on the success story of Lamda with its great team taking it to the next level while also continuing to support Clinigen as we focus on providing high-value services to the biopharma industry.”

Andreas Raabe, CEO of Adragos Pharma said that Lamda has an “impressive track record and professional service mindset,” adding: “Lamda combines differentiated product development capabilities with substantial scale, an essential combination for our international group.”

The exact terms of the transaction will not be disclosed.